Boehringer Ingelheim announces resolution of Cyltezo(R) patent litigation

Settlement provides Boehringer Ingelheim with a clear path to secure patient access to Cyltezo® in the U.S.

License period places Boehringer Ingelheim's biosimilar among the first to compete with Humira® in the U.S.

RIDGEFIELD, Conn., May 14,... Biopharmaceuticals, Litigation, Licensing Boehringer Ingelheim, AbbVie, Cyltezo, adalimumab, biosimilar, Humira

Source: HSMN NewsFeed - May 14, 2019 Category: Pharmaceuticals Source Type: news